These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
607 related articles for article (PubMed ID: 15198128)
1. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128 [TBL] [Abstract][Full Text] [Related]
2. Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. Bouvier C; Bartoli C; Aguirre-Cruz L; Virard I; Colin C; Fernandez C; Gouvernet J; Figarella-Branger D J Neurosurg; 2003 Aug; 99(2):344-50. PubMed ID: 12924709 [TBL] [Abstract][Full Text] [Related]
3. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. Rousseau A; Nutt CL; Betensky RA; Iafrate AJ; Han M; Ligon KL; Rowitch DH; Louis DN J Neuropathol Exp Neurol; 2006 Dec; 65(12):1149-56. PubMed ID: 17146289 [TBL] [Abstract][Full Text] [Related]
4. Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors. Aguirre-Cruz L; Mokhtari K; Hoang-Xuan K; Marie Y; Criniere E; Taillibert S; Lopes M; Delattre JY; Sanson M J Neurooncol; 2004 May; 67(3):265-71. PubMed ID: 15164981 [TBL] [Abstract][Full Text] [Related]
5. Expression of the oligodendroglial lineage-associated markers Olig1 and Olig2 in different types of human gliomas. Ohnishi A; Sawa H; Tsuda M; Sawamura Y; Itoh T; Iwasaki Y; Nagashima K J Neuropathol Exp Neurol; 2003 Oct; 62(10):1052-9. PubMed ID: 14575240 [TBL] [Abstract][Full Text] [Related]
6. Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas. Riemenschneider MJ; Koy TH; Reifenberger G Acta Neuropathol; 2004 Mar; 107(3):277-82. PubMed ID: 14730454 [TBL] [Abstract][Full Text] [Related]
7. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Lu QR; Park JK; Noll E; Chan JA; Alberta J; Yuk D; Alzamora MG; Louis DN; Stiles CD; Rowitch DH; Black PM Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10851-6. PubMed ID: 11526205 [TBL] [Abstract][Full Text] [Related]
8. OLIG2 as a specific marker of oligodendroglial tumour cells. Marie Y; Sanson M; Mokhtari K; Leuraud P; Kujas M; Delattre JY; Poirier J; Zalc B; Hoang-Xuan K Lancet; 2001 Jul; 358(9278):298-300. PubMed ID: 11498220 [TBL] [Abstract][Full Text] [Related]
9. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. Mokhtari K; Paris S; Aguirre-Cruz L; Privat N; Crinière E; Marie Y; Hauw JJ; Kujas M; Rowitch D; Hoang-Xuan K; Delattre JY; Sanson M Neuropathol Appl Neurobiol; 2005 Feb; 31(1):62-9. PubMed ID: 15634232 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants. Joseph NM; Phillips J; Dahiya S; M Felicella M; Tihan T; Brat DJ; Perry A Mod Pathol; 2013 Mar; 26(3):315-26. PubMed ID: 23041832 [TBL] [Abstract][Full Text] [Related]
11. Olig gene function in CNS development and disease. Ligon KL; Fancy SP; Franklin RJ; Rowitch DH Glia; 2006 Jul; 54(1):1-10. PubMed ID: 16652341 [TBL] [Abstract][Full Text] [Related]
12. Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas. Suzuki A; Nobusawa S; Natsume A; Suzuki H; Kim YH; Yokoo H; Nagaishi M; Ikota H; Nakazawa T; Wakabayashi T; Ohgaki H; Nakazato Y J Neurooncol; 2014 Nov; 120(2):283-91. PubMed ID: 25085214 [TBL] [Abstract][Full Text] [Related]
13. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179 [TBL] [Abstract][Full Text] [Related]
14. Nogo-A: a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q codeletion. Marucci G; Di Oto E; Farnedi A; Panzacchi R; Ligorio C; Foschini MP Hum Pathol; 2012 Mar; 43(3):374-80. PubMed ID: 21835431 [TBL] [Abstract][Full Text] [Related]
15. Predominant expression of OLIG2 over ID2 in oligodendroglial tumors. Mikami S; Hirose Y; Yoshida K; Kawase T; Ohnishi A; Nagashima K; Mukai M; Okada Y; Ikeda E Virchows Arch; 2007 May; 450(5):575-84. PubMed ID: 17431671 [TBL] [Abstract][Full Text] [Related]
16. OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms. Otero JJ; Rowitch D; Vandenberg S J Neurooncol; 2011 Sep; 104(2):423-38. PubMed ID: 21193945 [TBL] [Abstract][Full Text] [Related]
17. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Popova SN; Bergqvist M; Dimberg A; Edqvist PH; Ekman S; Hesselager G; Ponten F; Smits A; Sooman L; Alafuzoff I Histopathology; 2014 Feb; 64(3):365-79. PubMed ID: 24410805 [TBL] [Abstract][Full Text] [Related]
18. SOX10 and Olig2 as negative markers for the diagnosis of ependymomas: An immunohistochemical study of 98 glial tumors. Švajdler M; Rychlý B; Mezencev R; Fröhlichová L; Bednárová A; Pataky F; Daum O Histol Histopathol; 2016 Jan; 31(1):95-102. PubMed ID: 26287936 [TBL] [Abstract][Full Text] [Related]
19. Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. Lu QR; Sun T; Zhu Z; Ma N; Garcia M; Stiles CD; Rowitch DH Cell; 2002 Apr; 109(1):75-86. PubMed ID: 11955448 [TBL] [Abstract][Full Text] [Related]
20. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Cryan JB; Haidar S; Ramkissoon LA; Bi WL; Knoff DS; Schultz N; Abedalthagafi M; Brown L; Wen PY; Reardon DA; Dunn IF; Folkerth RD; Santagata S; Lindeman NI; Ligon AH; Beroukhim R; Hornick JL; Alexander BM; Ligon KL; Ramkissoon SH Oncotarget; 2014 Sep; 5(18):8083-92. PubMed ID: 25257301 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]